To include your compound in the COVID-19 Resource Center, submit it here.

Amylin targets Bydureon response by next week

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) reported 2Q11 results and said it plans to respond by next week to FDA's concerns about Type II diabetes

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE